In particular, immunohistochemical studies divided breast cancers into three major types with different related percentages and prognosis: estrogen (ER+) and progesterone (PR+) receptor—positive, human epidermal growth factor receptor 2 positive (HER2+), and triple negative breast cancers (TNBCs) (Figure 1). This evidence concerns the gene ERBB2 and breast carcinoma.